BerGenBio

BerGenBio ASA: Share capital increase

Bergen, Norway, 3 February 2022 - Reference is made to the stock exchange notice

published by BerGenBio ASA (the "Company") (OSE: BGBIO) on 27 January 2022 where

the Company announced that the board of directors of the Company had resolved to

increase the Company's share capital in connection with the exercise of options

pursuant to the Company's share option program. A total of 100,000 options were

exercised and 100,000 new shares were issued at an average subscription price of

NOK 15.33 per share.

The share capital increase has been duly registered in the Norwegian Register of

Business Enterprises. Following such registration, the Company's share capital

is NOK 8,855,525.50 divided into 88,555,255 shares, each with a nominal value of

NOK 0.10.

-End-

Contacts

Martin Olin

CEO, BerGenBio ASA

Rune Skeie

CFO, BerGenBio ASA

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and

other important factors. Such risks, uncertainties, contingencies and other

important factors could cause actual events to differ materially from the

expectations expressed or implied in this announcement by such forward-looking

statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal